ProPhase Labs, Inc. to Post Q1 2025 Earnings of $0.10 Per Share, Diamond Equity Forecasts (NASDAQ:PRPH)

ProPhase Labs, Inc. (NASDAQ:PRPH) – Diamond Equity issued their Q1 2025 earnings per share estimates for ProPhase Labs in a research report issued to clients and investors on Monday, April 22nd. Diamond Equity analyst H. Diamond anticipates that the company will post earnings of $0.10 per share for the quarter. The consensus estimate for ProPhase Labs’ current full-year earnings is ($0.88) per share. Diamond Equity also issued estimates for ProPhase Labs’ Q2 2025 earnings at $0.12 EPS, Q3 2025 earnings at $0.12 EPS and Q4 2025 earnings at $0.14 EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of ProPhase Labs in a research report on Wednesday, February 21st.

ProPhase Labs Stock Performance

NASDAQ PRPH opened at $5.06 on Wednesday. The company has a market capitalization of $91.33 million, a PE ratio of -5.16 and a beta of -0.29. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.10 and a current ratio of 2.28. ProPhase Labs has a 52-week low of $4.05 and a 52-week high of $9.94. The company has a 50-day simple moving average of $5.54 and a 200 day simple moving average of $5.00.

ProPhase Labs (NASDAQ:PRPH) last released its earnings results on Thursday, March 28th. The company reported ($0.51) EPS for the quarter. The business had revenue of $3.50 million for the quarter, compared to the consensus estimate of $10.71 million. ProPhase Labs had a negative return on equity of 29.83% and a negative net margin of 37.81%.

Institutional Investors Weigh In On ProPhase Labs

Several large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its position in shares of ProPhase Labs by 50.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 15,010 shares of the company’s stock worth $68,000 after acquiring an additional 5,026 shares in the last quarter. SVB Wealth LLC purchased a new position in shares of ProPhase Labs in the third quarter valued at $208,000. Finally, HighTower Advisors LLC bought a new stake in shares of ProPhase Labs during the 3rd quarter valued at $756,000. Hedge funds and other institutional investors own 9.45% of the company’s stock.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.